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Summary.-BDF' mice were inoculated with 106 leukaemic cells and, together with
control mice, were given a single oral dose of cyclophosphamide-14C of 100 mg/kg
body weight. In the leukaemic mice we observed an increased'4C concentration in
the plasma, bone marrow, liver, lungs, spleen, kidney and particularly fat where the
level was2-4 times higher than in control mice. Conversely, during the sameperiod,
significantly less 14C was detected in the stomach and small intestine of the leukaemic
mice. These results were obtained 6 days after tumour transplantation (median
survival time 7*7 days) whereas no differences were observed when the studies were
carried out 4 days after tumour transplantation. These findings indicate an increase
in the gastrointestinal absorption and in the tissue storage of cyclophosphamide in
L-1210 leukaemic mice at an advanced stage of the disease.
CYCLOPHOSPHAMIDE is used in the
treatment of a variety of human tumours,
including Hodgkin's disease and lympho-
mata, multiple myeloma and chronic and
acute leukaemia (Gershwin, Goetzl and
Steinberg, 1974). Besides the fact that
the drug must be metabolized by the
liver before exerting its cytotoxic activity
(Brock and Hohorst, 1962, 1967; Cohen
and Jao, 1970; Brock et al., 1971), other
factors such as absorption and selective
storage in some tissues might influence
the quality and duration of cyclophos-
phamide activity.
Such an hypothesis has led us to try
to establish, in BDF1 mice inoculated
with L-1210 leukaemia cells, a relationship
between the plasma concentration of
cyclophosphamide, its gastrointestinal ab-
sorption and its storage in some tissues.
The tests have been performed at an
advanced stage of the disease, with
appropriate controls.
To our knowledge, there is no pub-
lished study in which the metabolism
of cyclophosphamide has been measured
with a strict control over the stage of
the disease. This has been achieved by
consideration of the following parameters:
survival time, volume of ascitic fluid,
body weight, liver and spleen weights.
MATERIALS AND METHODS
Animals.-The first strain of L-1210
leukaemic mice were DBA/2 mice generously
supplied by the National Institute of Health
(Bethesda, U.S.A.). In ascitic form, the
L-1210 leukaemia was maintained by weekly
transplantations into BDF1 male mice
(C57BL/6 Y x DBA/2 ,) obtained from ARS
Sprague - Dawley, Madison, Wisconsin
(U.S.A.).
Tumourtransplantation.-BDF1 mice were
injected by the intraperitoneal route with
106 leukaemic cells taken from the ascitic
fluid of a leukaemic mouse. About 1 ml
of ascitic fluid was mixed with 2 ml of Locke
solution previously sterilized by ultrafiltra-
tion. After centrifugation, washings and a
viability test with trypan blue, the cells
were counted with a haemacytometer and
diluted to 1 million in 0-25 ml of Locke
solution.GASTROINTESTINAL ABSORPTION OF CYCLOPHOSPHAMIDE
Drugs. Cyclophosphamide (Procytox)
was obtained from Frank W. Horner Ltd,
Canada and cyclophosphamide monohydrate
(ring-5-14C) with a specific activity of 3-95
mCi/mmol, from New England Nuclear
Corp., Canada. Non-radioactive cyclo-
phosphamide (Procytox) was mixed with
cyclophosphamide-14C in distilled water and
a dose of 100 mg/kg containing about
1 ,tCi was given orally to each mouse. The
purity of both compounds was checked by
thin layer chromatography; 20 ,ul of either
solution (non-radioactive, radioactive) -%Aere
spotted on silica gel plates and the migration
performed in a bath containing a solvent
mixture of n-butanol-acetic acid-water
(6: 2 : 2) according to the technique of
Bus, Short and Gibson (1973). The chro-
matograms were developed with NBP and
KOH reagents (Friedman and Boger, 1961;
Hill, Laster and Struck, 1972); for 14C, the
radioactivity (plate divided in 1 cm sections)
was measured in a cocktail of 1 ml ofmethanol
plus 15 ml of toluene scintillator containing
POPOP and PPO (Bus et al., 1973).
Blue spots, indicating presence of al-
kylating metabolites, were not detected
either for unlabelled cyclophosphamide or
for the radioactive compound. For cyclo-
phosphamide-14C there was a single peak
of radioactivity that gave an Rf of 0-72.
Drug administration. Six days after tu-
mour transplantation, the mice were given
cyclophosphamide-14C orally using a single
dose of 100 mg/kg (about 1 pCi/mouse).
The mice had been deprived of food for
24 h, with water ad libitum. Five to 360
min following drug administration, the
animals (control and leukaemic) were killed
by decapitation.
Tissue distribution of cyclophosphamide.-
Plasma (100 jul) and tissue samples (100 mg)
including lungs, liver, kidney, fat (epi-
didymal), spleen and bone marrow (from the
2 femurs) were digested at 50°C in Soluene-
350 and 15 ml of scintillation cocktail
(POPOP and PPO in toluene) were added
and the samples counted in a Nuclear
Chicago liquid scintillation counter.
Gastrointestinal absorption of cyclophos-
phamide.-The stomach and small intestine
were tied at the cardia and pylorus levels,
and at the pylorus and caecum levels re-
spectively, and these tissues were removed.
The content and tissue of the stomach and
small intestine were digested in Soluene-350
and assayed for 14C activity. The results
are expressed as percentage of the dose
administered to the animal.
Cytology and histology.-Assessment of
tissue infiltration by malignant cells was
made on imprints and on histological sections
stained by standard methods (giemsa and
haemalum-eosin-safranin). These measures
were taken in mice killed 6 days after i.p.
inoculation of 106 leukaemic cells.
Statistical analysis. Significance of the
difference between control and leukaemic
mice was assessed by the Student's t test
and a P value of 0-05 or less was considered
significant.
RESULTS
Our criteria to evaluate the period
(evolution) of the disease were the follow-
ing: (1) median survival time (Fig. 1)
which was 7-7 days for 101 mice; (2) body
weight (Fig. 2): the control mice gained
2 g a week compared with 4-1 g for
leukaemic mice; (3) the ascitic fluid which
is present from the 4th day after tumour
transplantation and whose quantity
reaches a maximum at the 6th and 7th
days; (4) hepatomegaly and splenomegaly
(Table I); liver weight is 34% higher and
spleen weight 74U% higher in leukaemic
mice compared with control mice.
An assessment of the presence of
malignant cells in various tissues, in the
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FiG. 1. Median survival time (7 7 days) of
101 mice given 106 leukaemia cells on Day 0.
721
enJ.-G. LAVIGNE, A. BARRY, C. D AUTEUIL AND J.-M. DELAGE
5.0
w
C
.a
m
._
a
4.0
3.0
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
Days
FIG. 2. Body weight gain during survival time of mice given 106 leukaemia cells on Day 0
(0 * ), compared with body weight gain ofcontrol mice (luring the same pariod (0 * 0).
TABLE I.-Effect of Leukaemia on Spleen
Weight and Liver Weight of Mice given
106 Leukaemia Cells. (Figures in Paren-
theses refer to Number of Animals)
Groups
Control
Leukaemic
Spleen weight
(mg)
X±s.e.
47-9+25- (40)
83-5±4-6 (33)*
Liver weight
(g)
X s.e.
0 823±0* 039 (10)
105-10 045 (13)*
*P < 0*001.
TABLE II. Malignant
in Tissues, Ascites
Blood
Peripheral bloo(d
Bone marrow
Spleen
Liver
Lungs
Epididymal fat
Kidneys
Ascites
Lymphoid Cells
and Peripheral
Slight infiltration (30o)
Slight infiltration (40o)
Heavy infiltration (80%o)
Heavy infiltration
Heavy infiltration
Heavy infiltration
Slight infiltration
Complete infiltration
ascitic fluid and in the peripheral blood
has been made (Table II). The degree
of infiltration was measured quantita-
tively for blood, bone marrow and spleen,
a practice that could not be applied to
the other tissues such as liver, lungs,
kidneys and epididymal fat where the
density of infiltration had to be measured
in relation to the parenchymal tissue.
In plasma and other tissues the con-
centration of 14C is expressed in d/min
per ,ul or mg (except for bone marrow)
according to the counting efficiency for
each tissue.
In plasma (Fig. 3) the disappearance
curve of the drug is quite similar in both
groups. The curves indicate that the
gastrointestinal absorption is fast, with a
peak concentration in the plasma occur-
ring between 5 and 15 min. After 6 h,
the plasma is almost free of the drug.
Except at the 5 min reading, the plasma
concentration of 14C is always significantly
higher in the leukaemic group.
The 14C present in the bone marrow
from both femurs (Fig. 4), washed tho-
roughly with a fine needle and a known
volume of saline, was measured. Except
at the 2 extremities of the curve, the
concentration of 14C is significantly higher
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FIG. 3. Disappearance curves of radioactivity from the plasma of mice treated with cyclophos-
phamide-14C, 100 mg/kg (about 1 ,Ci/mouse), orally. Each point represents the mean of 9-10
mice. Vertical bars represent standard errors. Control mice: 0 *, leukaemic mice;
0- . *P < 0 05.
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FIG. 4. Disappearance curves of radioactivity from the bone marrow of mice treated with cyclo-
phosphamide-14C, 100 mg/kg (about 1 MCi/mouse), orally. Each point represents the mean
of 9-10 mice. Vertical bars represent standard errors. Control mice: * *, leukaemic
mice: * -. * P < 0 05.
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in the leukaemic group. With a peak
concentration at 15 min, the decay of
both curves is very slow between the 1st
and the 6th h.
In fat taken from the epididymal
area (Fig. 5) there is a striking accumula-
tion of 14C by the leukaemic mice com-
pared with control mice in which there
is a constant concentratioh up to 60 min,
followed by a slow release. Unlike the
other tissues, the peak concentration
for the leukaemic group is at 30 min, at
which interval the 14C concentration is
4 times higher than in the control group.
In other tissues (Fig. 6) there is again
an overall higher 14C concentration in
the leukaemic group and where there is
not, the differences are not significant.
Kidney shows the highest concentration,
being the principal site of excretion for
cyclophosphamide. Lungs, which are
richly vascularized, may reflect the blood
concentration, even though some unknown
metabolites might be excreted by this
route. The liver retains the second
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highest concentration, followed by the
spleen and lungs.
For the gastrointestinal absorption
of cyclophosphamide the results are ex-
pressed as the percentage of d/min (14C)
found in the stomach or small intestine,
or both. In the content and tissue of
the stomach (Fig. 7) we found less '4C
in the leukaemic group at every point
except 60 min, where the findings are
not significant. In the same Figure it
can be seen that the small intestine
(content and tissue) also contains signifi-
cantly less 14C in the leukaemic group,
except at 5 and 360 min.
Finally, in Fig. 8 we present the
compilation of 14C found in the gastro-
intestinal tract: much less 14C is found
in the leukaemic group compared with the
control group.
DISCUSSION
There is no doubt, as may be seen
from Figs. 3 and 8, that leukaemic mice
at an advanced stage of the disease
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FI(G. 5. Disappearance curves of radioactivity from the fat of mice treated with cyclophosphamide-
14C, 100 mg/kg (about 1 /LCi/mouse), orally. Each point represents the mean of 9-10 mice.
Vertical bars represent standard errors. Control mice: * leukaemic mice: ----0.
* P < 0 05.
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FIG. 6. Disappearance curves of radioactivity from lungs, spleeni, liver and kidney of mice treated
with cyclophosphamide-'4C, 100 mg/kg (about 1 ,Ci/mouse), orally. Each point represents the
mean of 9-10 mice. Vertical bars represent standard errors. Control mice: 0 0, leukaemic
mice: 0 ---0. * P < 0 05.
show an increased gastrointestinal absorp-
tion of cyclophosphamide. The correla-
tion between plasma concentration and
the percentage of the administered dose
which is found to be present in the
gastrointestinal tract indicates that the
leukaemic state influences the absorption
of cyclophosphamide in BDF1 mice.
In a study of the in vivo metabolism
of cyclophosphamide, such as the present
one, it is of prime importance to have
strict control of the evolution of the
disease. First of all, the samplings and
dosages have been made on the 6th day
following the inoculation of 106 leukaemic
cells. The median survival time of those
mice was 7-7 days (Fig. 1) so that at the
6th day the mice were at the terminal
stage. The reddish colour, together with
the quantity of ascitic fluid (2-3 ml),
constituted 2 additional criteria con-
firming the evolution of the disease. By
the 4th day ascitic fluid was present in
the peritoneal cavity and it was very
likely the main cause for the increase in
body weight (Fig. 2) in leukaemic mice.
To avoid misinterpretations of dosages
between leukaemic and control mice,
cyclophosphamide was administered on
the basis of body weight at Day 0, that
is on the day of inoculation; at that time,
all mice had a weight of 20-23 g. Due
to the invasion by leukaemic cells of
reticuloendothelial organs such as spleen
and liver, the regular observation of a
very significant hepatosplenomegaly by
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FIG. 7. Percentage of radioactivity recovered in stomach or small intestine, from 5 to 360 min
following an oral dose of cyclophosphamide-14C, 100 mg/kg (about 1 MCi/mouse). Each point
represents the mean of 9-10 mice. Vertical bars represent standard errors. Control mice:
* *, leukaemic mice: 0 ----. * P < 0 05.
the 6th day (Table I) came as no surprise.
In addition, the liver had a markedly
pale appearance on section and was very
friable.
As far as the plasma disappearance
curve is concerned, the results are com-
parable with those obtained using different
methods of adhiinistration: in newborn
mice, the clearance of radioactivity after
subcutaneous administration was first
order with a half-life of 8-76 h (Bus et
al., 1973). In normal mice the clearance
of alkylating activity from the blood
after a 180 mg/kg intraperitoneal dose
was virtually complete within 3 h and
alkylating metabolites reached peak plas-
ma concentration at 10-15 min (Gibson
and Becker, 1968; Field et al., 1972).
In the bone marrow sampled from the
2 femurs (Fig. 4) an interesting finding
was the significant increase in radio-
activity, except at 5 min, in leukaemic
mice. This could not be simply a re-
flexion of plasma concentration since an
almost constant level of 14C has been
found between 60 and 360 min, a fact
that seems to indicate a selective con-
centration of the drug at its main site
of cytotoxical action (Greenwald, 1973).
The strong increase in radioactivity
in the fat tissues of the leukaemic mice
(Fig. 5) should be stressed. It is 2-4
times that of the control mice. The fact
might be explained in 2 ways: either
leukaemic mice have an increased capacity
for storing the drug in their fat tissues,
due to mechanisms presently unknown,
or there might be a decreased biotrans-
formation of cyclophosphamide in the
liver so that the drug itself would con-
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Fic.. 8. Percentage of radioactivity recovered in the gastrointestinal tract (stomach + small
intestine), from 5 to 360 min following an oral dose of cyclophosphamide-14C, 100 mg/kg (about
1 ,Ci/mouse). Each point represents the mean of 9-10 mice. Vertical bars represent standard
errors. Control mice: * *, leukaemic mice: 0 ----. * P < 0 05.
centrate in the fat tissues, in lieu of
its own metabolites. As demonstrated
by several authors, the liver drug meta-
bolizing enzyme activity is reduced in
tumour bearing animals, leading to in-
creased levels of unchanged drug and
increased pharmacological effect or toxi-
city (Kato et al., 1968; Kato, Takanaka
and Oshima, 1968; Rosso, Dolfini and
Donelli, 1968; Rosso et al., 1971; Bartosek
et al., 1975; Beck, Mandel and Fabro,
1971, 1975). Such a comparison between
control and leukaemic mice is interesting
because until now unusually high localiza-
tion of cyclophosphamide in a specific
organ has not been reported (Torkelson,
LaBudde and Weikel, 1974).
The distribution of the drug in the
other tissues seems to reflect what was
observed in plasma, that is a regular
and significantly increased concentration
of 14C in leukaemic mice compared with
control mice (Fig. 6). Whereas the plas-
ma disappearance curve had indicated a
rapid absorption of the drug with a
peak at 15 min, the concentration of
14C in the kidneys, which constitute
the principal excretory pathway for cyclo-
phosphamide in several animal species
(Torkelson et al., 1974) as in man (Bagley,
Bostick and DeVita, 1973), would seem
to indicate a rapid elimination. How-
ever, it had been noted that in mice
(Torkelson et al., 1974) as much as 20%
of the radioactivity was excreted as
14CO 2 a fact that would explain the
concentrations of 14C that have been
found in the lungs. The high concentra-
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tion in the liver can be explained by the
important role played by this organ in
the biotransformation of cyclophospha-
mide into cytotoxic alkylating metabolites
(Brock and Hohorst, 1962, 1967; Cohen
and Jao, 1970; Brock et al., 1971; Sladek,
1972). In mice, the initial oxidative
step in cyclophosphamide metabolism is
performed by the microsomal mixed
function oxidase system of the liver to
yield 4-hydroxy cyclophosphamide (Sla-
dek, 1972) which is converted to aldo-
phosphamide; aldophosphamide is very
toxic to L-1210 leukaemia cells (Hill et
al., 1972) and is further oxidized, probably
by liver aldehyde oxidase, to carboxy-
phosphamide, a metabolite which has
little or no anti-tumour effect on L-1210
cells (Hill et al., 1972). More recently,
volatile metabolites, possibly produced
within the tumour cell but not in the
liver, have been isolated, e.g. acrolein
(Thomson and Colvin, 1974) and phos-
phoramide mustard (Connors et al., 1974);
these 2 metabolites are toxic to L-1210
leukaemia cells and Walker tumour cells.
From these studies it appears that the
complex mode of activation of cyclo-
phosphamide is not completely resolved
(Chabner et al., 1975) and that at least
2 of the known active metabolites (aldo-
phosphamide and acrolein) are indeed
labelled with the ring 5-14C material used
in our study (see Fig. 8 in Cliabner et
al., 1975).
In the past few years it has been
demonstrated that Ehrlich ascites tumour
bearing mice (Beck et al., 1975) or spon-
taneous tumour bearing mice (Sharma
and Garb, 1974) as well as Walker 256
carcinoma bearing rats (Rosso et al.,
1968; Franchi and Rosso, 1969) cleared
drugs (pentobarbitone or zoxazolamine)
more slowly than did the normal animals.
According to our findings with cyclo-
phosphamide, the increased plasma and
tissue radioactivity concentration in leuk-
aemic mice could be explained by an
increase in the absorption of cyclo-
phosphamide at the gastric level as well
as at the small intestine level (Fig. 7)
(see Fig. 8 for a summary). The hypo-
thesis might be advanced that an increase
in gastrointestinal motility would facilitate
the transit of the drug and accelerate
its passive diffusion to the blood. There
may also be an increased blood flow at
the level of the gastrointestinal tract
in leukaemic mice. The actual mech-
anism remains to be demonstrated. XVe
may add, from the data appearing in
Table II, that a definite correlation can
hardly be made between the degree of
tissue infiltration by malignant cells and
drug uptake by the same tissues.
It is important to note that the
experiments were also performed on
leukaemic mice 4 days after the inocula-
tion of 106 leukaemic cells and that, at
that stage, there was no difference be-
tween leukaemic and control mice as
far as the metabolism (gastrointestinal
absorption, plasma and tissue concen-
tration) of cyclophosphamide was con-
cerned.
In conclusion, our findings confirm
the importance of a pharmacokinetic
approach in the study of antineoplastic
drugs (Balconi et al., 1973; Bischoff,
1973; Mellet, 1974; Bossi et al., 1975)
even if it is well known that the efficacy
of cyclophosphamide is dependent on
its biotransformation by the liver (Sladek
1972). Leukaemic mice at an advanced
stage of the disease do not metabolize
cyclophosphamide as the controls, or as
they themselves do at an earlier stage
of their disease. Such findings, if they
can be extrapolated to man, would
indicate the need for an adequate control
of cyclophosphamide administration, par-
ticularly with regard to avoiding excess
concentrations leading to intolerable side-
effects.
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